March 3, 2021
March 3, 2021 – The U.S. FDA has approved AzstarysTM (serdexmethylphenidate/dexmethylphenidate), manufactured by Corium, to treat attention deficit hyperactivity disorder (ADHD) in
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
GlobalReach Health
March 3, 2021
March 3, 2021 – The U.S. FDA has granted Pfizer’s Lorbrena® (lorlatinib) full approval after first issuing an
accelerated approval in 2018. The agency has also expanded Lorbrena’s approved
March 2, 2021
March 2, 2021 - Drug recalls are more common than many consumers realize, and in most cases present little to no immediate danger to anyone. While common recalls might sound like a bad thing
March 1, 2021
March 1, 2021 – Merck, the manufacturer of Keytruda® (pembrolizumab), has voluntarily withdrawn the
drug’s FDA-approved indication to provide third-line treatment of metastatic small cell
February 28, 2021
February 28, 2021 – The U.S. FDA has approved NulibryTM (fosdenopterin), manufactured by BridgeBio
Pharma, to reduce the risk of death due to molybdenum cofactor deficiency (MoCD) Type A
February 27, 2021
The U.S. FDA has granted Emergency Use Authorization (EUA) to Johnson & Johnson’s
COVID-19 vaccine, which is manufactured by the Johnson & Johnson subsidiary
February 26, 2021
February 26, 2021 – The U.S. FDA has approved Pepaxto® (melphalan flufenamide), manufactured by Oncopeptides, for use in conjunction with dexamethasone to treat relapsed or
February 25, 2021
February 25, 2021 - Since the start of the pandemic, affordable and sustainable access to oxygen has been a growing challenge in low- and middle-income countries.